Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan 3;32(2):214-6.
doi: 10.1016/j.vaccine.2013.11.025. Epub 2013 Nov 16.

Vaccination of cattle with a recombinant bivalent toxoid against botulism serotypes C and D

Carlos E P Cunha  1 , Gustavo M S G Moreira  1 , Felipe M Salvarani  2 , Monique S Neves  2 , Francisco C F Lobato  2 , Odir A Dellagostin  1 , Fabricio R Conceição  3
Affiliations

Vaccination of cattle with a recombinant bivalent toxoid against botulism serotypes C and D

Carlos E P Cunha et al. Vaccine. .

Abstract

Cattle botulism is a fatal intoxication caused by botulinum neurotoxins (BoNTs) produced by Clostridium botulinum serotypes C and D resulting in economic losses. Vaccination is the most effective way to control botulism. However, the commercially available vaccines are difficult and hazardous to produce. Neutralizing antibodies against the C-terminal fragment of the BoNT heavy chain (HC) are known to protect against lethal doses of BoNTs. We report the vaccination of cattle with a previously tested recombinant chimera consisting of Escherichia coli heat-labile enterotoxin B subunit and the HC of BoNTs C and D. Vaccinated animals produced neutralizing antibodies against serotypes C and D averaging 5±0 and 6.14±1.06IU/mL, respectively. For BoNT D, the titers were greater than those measured for the commercial vaccine, which induced titers of 5±0 and 2.85±1.35 against the respective serotypes, suggesting that this chimera is effective against cattle botulism.

Keywords: Botulinum neurotoxins; Clostridium botulinum; Fused antigens; LTB; Recombinant vaccine.

PubMed Disclaimer